Takeda May Resurrect IDM’s Bone Cancer Drug Mifamurtide In U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
Fate of IDM’s dendritic cell-based Uvidem and other cancer vaccines remains unclear after $75 million purchase.